For the year ending 2025-12-31, WVE had $300,036K increase in cash & cash equivalents over the period. -$188,211K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -204,378 |
| Amortization of right-of-use assets | 5,412 |
| Depreciation of property and equipment | 3,440 |
| Share-based compensation expense | 24,973 |
| Accounts receivable | -146 |
| Prepaid expenses | -1,149 |
| Other assets | -4,314 |
| Accounts payable | -561 |
| Accrued expenses and other current liabilities | 5,483 |
| Deferred revenue | -19,833 |
| Operating lease liabilities | -7,638 |
| Other non-current liabilities | 0 |
| Net cash used in operating activities | -187,493 |
| Purchases of property and equipment | 718 |
| Net cash used in investing activities | -718 |
| Proceeds from issuance of ordinary shares-December Two Thousand Twenty Five Offering | 330,912 |
| Proceeds from issuance pre-funded warrants, net of offering costs-December Two Thousand Twenty Five Offering | 46,938 |
| Proceeds from issuance of ordinary shares pursuant to the at-the-market equity program, net | 94,636 |
| Proceeds from the exercise of share options | 14,868 |
| Proceeds from the espp | 881 |
| Net cash provided by financing activities | 488,235 |
| Effect of foreign exchange rates on cash | 12 |
| Net increase in cash, cash equivalents and restricted cash | 300,036 |
| Cash, cash equivalents and restricted cash, beginning of period | 305,838 |
| Cash, cash equivalents and restricted cash, end of period | 605,874 |
Wave Life Sciences Ltd. (WVE)
Wave Life Sciences Ltd. (WVE)